Riskpilot← Back to searchSign inGet full accessTestfakta Bio-based Europe AB
ABActiveOrg 5591754485Drottninggatan 81 A 3trTechnical testing and analysis · NACE 7120Est. 20180 employees
Revenue 2025
SEK 77K
+178% vs 2024
EBITDA margin
39.1%
+19224% vs 2024
Equity ratio
92.8%
Financial strength
Net profit 2025
SEK -3K
0% vs 2024
| Revenue | SEK 77K | +178% |
| EBITDA | SEK 30K | +19224% |
| Net profit | SEK -3K | +0% |
| Total assets | SEK 359K | +0% |
| Equity | SEK 334K | -1% |
| Employees | 0 | — |
Legal name
Testfakta Bio-based Europe AB
Org number
5591754485
Legal form
Aktiebolag
NACE code
7120 · Technical testing and analysis
Founded
16 oktober 2018
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget skall bedriva verksamhet inom området kemisk analys, utvärdering och certifiering av produkter och råvaror samt utföra tjänster på konsultbasis inom området kemisk analys och därmed förenlig verksamhet.
Address
Drottninggatan 81 A 3tr
Email
info@testfakta.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 28 | 72 | 59 | 28 | 77 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −68 | −14 | 16 | 0 | 30 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −68 | −14 | 16 | 0 | 30 |
| Net financials | −41 | −12 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 290 | −3 | −3 |
| Tax | −0 | — | — | — | — |
| Net profit | 0 | 0 | 290 | −3 | −3 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 458 | 89 | 365 | 360 | 359 |
| Equity | 50 | 50 | 340 | 337 | 334 |
| Long-term debt | 152 | 0 | — | — | — |
| Short-term debt | 255 | 39 | 26 | 24 | 26 |
| Total debt | 407 | 39 | 26 | 24 | 26 |
EBITDA margin
39.1%
This company
15.8%
Market median
+147% vs market
20212025
Equity ratio
92.8%
This company
38.2%
Market median
+143% vs market
20212025
Return on equity
-0.9%
This company
18.4%
Market median
-105% vs market
20212025
Net profit margin
-4.1%
This company
8.1%
Market median
-151% vs market
20212025
Asset turnover
0.21×
This company
1.12×
Market median
-81% vs market
20212025
Debt / equity
0.08×
This company
0.62×
Market median
+87% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
BO Chief Auditor | Chief Auditor | 2026 |
KP Chief Executive Officer | Chief Executive Officer | 2021 |
| Former (2) | ||
JP Chief Auditor | Chief Auditor | 2022 – 2026 |
FG | Audit | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2020 | |
| Chairman | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Testfakta Group Nordic Aktiebolag
Testfakta Bio-based Europe AB Board members of Testfakta Bio-based Europe AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bo Oskar Nyström | Chief Auditor | 0 companies |
| Johan Paul Christophe Grudet | Chief Auditor | 0 companies |
| Fredrik Gunnar Petersson | Audit | 0 companies |
| Klaus Peter Hahn | Chief Executive Officer | 0 companies |
| Anne Catarina Malmström | Deputy Board Member | 0 companies |
| Bengt Mikael Vernberg | Chairman | 0 companies |